- Home
- QS vs PRAX Comparison
QS vs PRAX Comparison
Compare QS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QS | PRAX |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 8.8B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | QS | PRAX |
|---|---|---|
| Price | $10.96 | $312.37 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $9.06 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 12.5M | 623.7K |
| Earning Date | 02-11-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,463,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $14,827.76 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 364.98 |
| 52 Week Low | $3.40 | $26.70 |
| 52 Week High | $19.07 | $326.91 |
Technical Indicators
Market Signals| Indicator | QS | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 63.20 |
| Support Level | $10.05 | $266.93 |
| Resistance Level | $10.98 | $326.91 |
| Average True Range (ATR) | 0.58 | 17.87 |
| MACD | 0.06 | 0.13 |
| Stochastic Oscillator | 56.91 | 75.94 |
Price Performance
Historical ComparisonAbout QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.